Siemens Healthineers aims for $300 million in savings
Reuters
Published Nov 09, 2022 01:29AM ET
Updated Nov 09, 2022 07:40AM ET
By Alexander Huebner
ERLANGEN, Germany (Reuters) - Siemens Healthineers will restructure its diagnostics division to save around 300 million euros ($302 million) each year starting from 2025, the U.S.-German medical device maker said on Wednesday.
It said it would spend a similar amount on the overhaul, although those costs would be one-off, while the savings will recur.
Shares in Siemens Healthineers were up almost 2% by 1126 GMT following the announcement.
After the introduction of its Atellica laboratory system, older systems - most of them acquisitions - are to be taken off the market sooner than previously planned to simplify the portfolio.
For the fiscal year that started in October, Healthineers has budgeted costs of 150 million to 200 million euros for the restructuring, a presentation to shareholders shows.
Up to 2025, the overhaul is expected to cost between 350 million and 450 million euros, Chief Executive Bernd Montag said in Erlangen on Wednesday.
He said the restructuring would mean less focus on certain locations for the diagnostics division, with fewer staff required in some areas.
Sources from within the company said the plan involves cutting jobs and abandoning certain locations.
Siemens Healthineers also said it was lowering its targets for the laboratory division, with comparable sales growth of 3%-5% per year until 2025, rather than 4-6% previously. The adjusted return on sales before interest and taxes (EBIT margin) is seen at 8%-12% by 2025 instead of a previously hoped-for 15%.
The group targets adjusted basic earnings per share of between 2 euros and 2.20 euros for fiscal 2023.
During fiscal 2022, it achieved comparable revenue growth of 5.9% at around 21.7 billion euros. This compared with a targeted range of 5.5% to 7.5% and analysts' average estimate of 21.5 billion euros in revenue.
Full-year net income rose by 18% to 2.05 billion euros, partly as a result of lucrative business with COVID-19 tests.
The company proposed a 10 cent dividend increase to 0.95 euros.
($1 = 0.9943 euros)
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.